Maya Ridinger

466 total citations
41 papers, 302 citations indexed

About

Maya Ridinger is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Maya Ridinger has authored 41 papers receiving a total of 302 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in Maya Ridinger's work include Cancer Treatment and Pharmacology (16 papers), Cancer Genomics and Diagnostics (9 papers) and Acute Myeloid Leukemia Research (8 papers). Maya Ridinger is often cited by papers focused on Cancer Treatment and Pharmacology (16 papers), Cancer Genomics and Diagnostics (9 papers) and Acute Myeloid Leukemia Research (8 papers). Maya Ridinger collaborates with scholars based in United States, Italy and United Kingdom. Maya Ridinger's co-authors include Mark G. Erlander, Errin Samuëlsz, R. Nutt, Yvonne T. Maddox, Peter W. Ramwell, Pamela S. Becker, Eunice S. Wang, Amer M. Zeidan, Sandra Silberman and Tara L. Lin and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Maya Ridinger

38 papers receiving 299 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Maya Ridinger United States	9	155	118	74	51	46	41	302
Efrat Flashner-Abramson Israel	10	230 1.5×	150 1.3×	26 0.4×	35 0.7×	97 2.1×	13	393
Yao Tian China	14	284 1.8×	108 0.9×	54 0.7×	57 1.1×	148 3.2×	39	457
K Ito Japan	9	196 1.3×	94 0.8×	66 0.9×	36 0.7×	92 2.0×	15	351
Ivana Galetić Switzerland	7	315 2.0×	64 0.5×	31 0.4×	107 2.1×	48 1.0×	10	494
Shunsuke Ebara Japan	7	208 1.3×	68 0.6×	65 0.9×	31 0.6×	88 1.9×	15	325
Christine Pellegrino United States	10	261 1.7×	230 1.9×	37 0.5×	59 1.2×	62 1.3×	13	448
Tatiana Y. Prudnikova Russia	13	267 1.7×	97 0.8×	149 2.0×	56 1.1×	78 1.7×	21	404
Sreesha P. Srinivasa United States	7	438 2.8×	67 0.6×	93 1.3×	36 0.7×	19 0.4×	16	518
Xiaomei Sui China	11	330 2.1×	110 0.9×	82 1.1×	41 0.8×	112 2.4×	21	449
Irene García‐Palmero Spain	12	249 1.6×	131 1.1×	57 0.8×	47 0.9×	102 2.2×	14	415

Countries citing papers authored by Maya Ridinger

Since Specialization

Citations

This map shows the geographic impact of Maya Ridinger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maya Ridinger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maya Ridinger more than expected).

Fields of papers citing papers by Maya Ridinger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maya Ridinger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maya Ridinger. The network helps show where Maya Ridinger may publish in the future.

Co-authorship network of co-authors of Maya Ridinger

This figure shows the co-authorship network connecting the top 25 collaborators of Maya Ridinger. A scholar is included among the top collaborators of Maya Ridinger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maya Ridinger. Maya Ridinger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liu, Sheng, Jun Wan, Steven P. Angus, et al.. (2025). PLK1 Inhibition Induces Synthetic Lethality in Fanconi Anemia Pathway–Deficient Acute Myeloid Leukemia. Cancer Research Communications. 5(4). 648–667. 1 indexed citations

Guffanti, Federica, Francesca Ricci, Robert Fruscio, et al.. (2025). Onvansertib-Based Second-Line Therapies in Combination with Gemcitabine and Carboplatin in Patient-Derived Platinum-Resistant Ovarian Carcinomas. International Journal of Molecular Sciences. 26(12). 5708–5708.

Nouri, Mannan, Andreas Varkaris, Maya Ridinger, et al.. (2024). AKT Inhibition Sensitizes to Polo-Like Kinase 1 Inhibitor Onvansertib in Prostate Cancer. Molecular Cancer Therapeutics. 23(10). 1404–1417. 3 indexed citations

Sreekumar, Sreeja, Pierre Painsec, Laura Sourd, et al.. (2024). Abstract PO2-04-09: Combination of the PLK1 Inhibitor Onvansertib and the PI3Kα Inhibitor Alpelisib Overcomes Palbociclib Resistance in PIK3CA-mutated HR+ Breast Cancer. Cancer Research. 84(9_Supplement). PO2–4. 1 indexed citations

Ahn, Daniel H., Maya Ridinger, Timothy Lewis Cannon, et al.. (2024). Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial. Journal of Clinical Oncology. 43(7). 840–851. 11 indexed citations

Sreekumar, Sreeja, Élodie Montaudon, Pierre Painsec, et al.. (2024). PLK1 Inhibitor Onvansertib Enhances the Efficacy of Alpelisib in PIK3CA-Mutated HR-Positive Breast Cancer Resistant to Palbociclib and Endocrine Therapy: Preclinical Insights. Cancers. 16(19). 3259–3259. 1 indexed citations

Ahn, Daniel H., Afsaneh Barzi, Maya Ridinger, et al.. (2024). Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study. Clinical Cancer Research. 30(10). 2039–2047. 20 indexed citations

Croucher, Peter J.P., Maya Ridinger, Pamela S. Becker, et al.. (2023). Spliceosome mutations are associated with clinical response in a phase 1b/2 study of the PLK1 inhibitor onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia. Annals of Hematology. 102(11). 3049–3059. 6 indexed citations

Patterson, Jesse C., Andreas Varkaris, Peter J.P. Croucher, et al.. (2022). Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling. Cancer Research. 83(2). 219–238. 12 indexed citations

10.

Lenz, Heinz‐Josef, Anup Kasi, Timothy Lewis Cannon, et al.. (2022). A phase 1b/2 trial of the PLK1 inhibitor onvansertib in combination with FOLFIRI-bev in 2L treatment of KRAS-mutated (mKRAS) metastatic colorectal carcinoma (mCRC).. Journal of Clinical Oncology. 40(4_suppl). 100–100. 7 indexed citations

11.

Affatato, Roberta, Michela Chiappa, Federica Guffanti, et al.. (2022). Onvansertib and paclitaxel combined in platinum-resistant ovarian carcinomas. Therapeutic Advances in Medical Oncology. 14. 4287507096–4287507096. 3 indexed citations

12.

Ahn, Daniel H., Maya Ridinger, Mark G. Erlander, Tanios Bekaii‐Saab, & Heinz‐Josef Lenz. (2021). A phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second-line treatment of patients with KRAS-mutated metastatic colorectal Cancer (mCRC).. Journal of Clinical Oncology. 39(3_suppl). TPS155–TPS155. 2 indexed citations

13.

Zeidan, Amer M., Maya Ridinger, Tara L. Lin, et al.. (2020). A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia. Clinical Cancer Research. 26(23). 6132–6140. 57 indexed citations

14.

Wang, Xiaolong, Bingsheng Li, Anna Ciotkowska, et al.. (2020). Onvansertib, a polo-like kinase 1 inhibitor, inhibits prostate stromal cell growth and prostate smooth muscle contraction, which is additive to inhibition by α1-blockers. European Journal of Pharmacology. 873. 172985–172985. 18 indexed citations

15.

Ahn, Daniel H., Mark G. Erlander, Maya Ridinger, et al.. (2020). 436P Phase Ib/II study of the polo-like kinase 1 (PLK1) inhibitor, onvansertib, in combination with FOLFIRI and bevacizumab for second line treatment of KRAS-mutated metastatic colorectal cancer. Annals of Oncology. 31. S427–S427. 5 indexed citations

16.

Barzi, Afsaneh, Heinz‐Josef Lenz, Errin Samuëlsz, et al.. (2020). Abstract CT235: A phase 1b/2 study of onvansertib (PCM-075) in combination with FOLFIRI and bevacizumab for second line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC). Cancer Research. 80(16_Supplement). CT235–CT235. 1 indexed citations

17.

Einstein, David J., Atish D. Choudhury, Philip J. Saylor, et al.. (2020). A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 38(6_suppl). TPS266–TPS266. 4 indexed citations

18.

Liu, Yueying, Kent Armeson, Yeonhee Park, et al.. (2019). Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer. TUScholarShare (Temple University). 1 indexed citations

19.

Liu, Yueying, Kent Armeson, Yeonhee Park, et al.. (2019). Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer. PLoS ONE. 14(11). e0224420–e0224420. 31 indexed citations

20.

Nutt, R., et al.. (2007). In Vivo Molecular Imaging Biomarkers: Clinical Pharmacology’s new “PET”?. Clinical Pharmacology & Therapeutics. 81(6). 792–795. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact